Get the Stockscreener App
6.20
4.47%
-0.29
Kura Oncology Inc stock is traded at $6.20, with a volume of 1.30M.
It is down -4.47% in the last 24 hours and up +2.99% over the past month.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
See More
Previous Close:
$6.49
Open:
$6.45
24h Volume:
1.30M
Relative Volume:
1.03
Market Cap:
$589.57M
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-2.8571
EPS:
-2.17
Net Cash Flow:
$-138.01M
1W Performance:
-8.96%
1M Performance:
+2.99%
6M Performance:
-36.34%
1Y Performance:
-70.03%
1-Day Range:
$6.18
$6.56
1-Week Range:
$6.18
$7.17
52-Week Range:
$5.41
$23.48
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Compare KURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
6.20 | 589.57M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
Kura Oncology rises after new early-stage trial data for leukemia therapy - MSN
Pallas Capital Advisors LLC Invests $66,000 in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Harbor Capital Advisors Inc. - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook By Investing.com - Investing.com South Africa
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook - Investing.com Canada
KURA's Ziftomenib Shows Promising Results in AML Clinical Trial - GuruFocus
Kura Oncology reports positive data for AML treatment ziftomenib By Investing.com - Investing.com South Africa
Kura Oncology (KURA) Shows Promising Results for AML Therapy - GuruFocus
Is the Options Market Predicting a Spike in Kura Oncology Stock? - Nasdaq
Kura Oncology Says Ziftomenib Study Achieves Complete Remission in Acute Myeloid Leukemia - marketscreener.com
Kura Oncology stock rises on leukemia drug data (KURA:NASDAQ) - Seeking Alpha
Is The Options Market Predicting A Spike In Kura Oncology Stock? - Barchart.com
Kura Oncology and Kyowa Kirin Report Positive Updated Combinatio - GuruFocus
Kura Oncology’s SWOT analysis: ziftomenib stock potential in AML treatment By Investing.com - Investing.com Canada
Kura Oncology and Kyowa Kirin Report Strong Results from KOMET-007 Trial of Ziftomenib in Newly Diagnosed AML Patients - Nasdaq
Kura Oncology reports positive data for AML treatment ziftomenib - Investing.com
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly ... - Enidnews.com
Groundbreaking AML Trial: Ziftomenib Achieves 93% Complete Remission in Blood Cancer Patients - Stock Titan
Kura Oncology’s SWOT analysis: ziftomenib stock potential in AML treatment - Investing.com
Cantor Fitzgerald Forecasts Kura Oncology FY2026 Earnings - Defense World
KURA Stock Rises More Than 15% This Past Week: Here's Why - MSN
Kura Oncology at Goldman Sachs Conference: Strategic Insights on ZIFTOMENIB - Investing.com Canada
Transcript : Kura Oncology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 11 - marketscreener.com
Kura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Ameriprise Financial Inc. Acquires New Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology Stockholders Approve Equity Plan Amendment - TipRanks
Kura Oncology Grants Stock Options To New Hires Under Inducement Plan - Nasdaq
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rul - GuruFocus
Kura Oncology (KURA) Grants Stock Options to New Employees | KUR - GuruFocus
Kura Oncology (KURA) Grants Stock Options to New Employees | KURA Stock News - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KURA Stock News - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Kura Oncology Expands Cancer Research Team with Strategic Stock Options for 5 Key New Hires - Stock Titan
Kura Oncology’s (KURA) “Market Outperform” Rating Reaffirmed at JMP Securities - Defense World
Kura Oncology at Jefferies Conference: Strategic Advancements in AML By Investing.com - Investing.com Canada
**citizens jmp reiterates market outperform rating on kura oncology stock** - Investing.com UK
Two Sigma Investments LP Sells 42,120 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Rising Leaders 2025: Kura Oncology’s Mollie Leoni On Setting Precedent, Not Following It - insights.citeline.com
Nuveen Asset Management LLC Lowers Stock Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Transcript : Kura Oncology, Inc. Presents at American Society of Clinical Oncology Annual Meeting 2025, Jun-02-2025 06 - marketscreener.com
Kura Oncology Drug’s Data at ASCO Support FDA Filing Now Under Priority Review for Leukemia - MedCity News
KURA: Optimism for Kura Oncology's Menin Inhibitor Grows with FDA Priority Review | KURA Stock News - GuruFocus
Cantor Fitzgerald reiterates overweight rating for Kura Oncology stock By Investing.com - Investing.com Nigeria
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting - The Manila Times
Kura Oncology reports positive trial results for AML treatment By Investing.com - Investing.com South Africa
Kura Oncology at ASCO: Strategic Moves in AML Treatment By Investing.com - Investing.com Canada
Kura Oncology reports positive trial results for AML treatment - Investing.com Australia
KURA: Promising Results for Kura Oncology's AML Therapy at ASCO Meeting | KURA Stock News - GuruFocus
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib - GuruFocus
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting | KURA Stock News - GuruFocus
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):